Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
32 hedge funds and large institutions have $61.2M invested in Avadel Pharmaceuticals in 2013 Q2 according to their latest regulatory filings, with 32 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
47% more call options, than puts
Call options by funds: $110K | Put options by funds: $75K
Top Buyers
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Barclays
London,
United Kingdom
| $19K | +$16.1K | +3,127 | New |
|
|
TRCT
27
Tower Research Capital (TRC)
New York
| $8K | +$7.13K | +1,380 | New |
|
|
WC
28
Whitnell & Co
Oak Brook,
Illinois
| $3K | +$2.58K | +500 | New |
|
29
Wells Fargo
San Francisco,
California
| $1K | +$1.03K | +200 | New |
|
30
Citigroup
New York
| $1K | +$1.2K | +233 | New |
|
31
Ameriprise
Minneapolis,
Minnesota
| – | +$108 | +21 | New |
|
32
Bank of America
Charlotte,
North Carolina
| – | +$284 | +55 | New |
|
AVDL Hedge Fund Activity: Q2 2013 in Review
32 of the 3,065 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q2 2013, worth a combined $61.2M.
Buyers outnumbered sellers: 32 funds opened new AVDL positions and 0 closed out — a net gain of 32 holders — while 0 added to existing stakes and 0 trimmed.
- 32 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q2 2013, up from 0 in Q1 2013.
- Funds reported $61.2M of Avadel Pharmaceuticals stock for Q2 2013.
- 32 funds opened new Avadel Pharmaceuticals positions in Q2 2013 and 0 closed out, a net change of +32 holders.
Based on aggregated 13F filings for Q2 2013.